Vitamin A prevents disease/death in young children

Article

A new Cochrane meta-analysis shows that giving vitamin A capsules to children from 6 months to 5 years of age reduces deaths as well as the incidence of certain illnesses.

 

A new Cochrane meta-analysis shows that giving vitamin A capsules to children from 6 months to 5 years of age reduces deaths as well as the incidence of certain illnesses. Vitamin A deficiency, which causes a significant public health problem in low- and middle-income countries, predisposes children to a range of problems, including respiratory diseases, diarrhea, measles, vision problems-and even death.

Researchers included in their investigation 43 randomized trials enrolling 215,633 children that evaluated the effect of synthetic vitamin A supplementation. Studies concerned with hospitalized children and children with disease or infection, as well as those evaluating the effects of food fortification, consumption of vitamin A-rich foods, or beta-carotene supplementation were excluded. Investigators carried out meta-analyses for all-cause and cause-specific mortality, disease, vision, adverse effects, and other outcomes.

One of these meta-analyses was of all-cause mortality in 17 trials enrolling a total of 194,795 children, of whom 3,536-some supplemented and some not-died. Children who received vitamin A supplementation had a 24% overall reduced risk of death compared with children who did not receive the supplements. Of 7 trials reporting mortality from diarrhea, vitamin A supplementation reduced deaths by 28%. Supplementation had no significant effect on cause-specific death because of measles, respiratory infections, or meningitis.

Vitamin A supplementation reduced incidence of diarrhea and measles morbidity but had no significant effect on the incidence or respiratory disease or hospitalizations because of diarrhea or pneumonia. Taking vitamin A raised the risk of vomiting up to 48 hours after supplementation.

Imdad A, Herzer K, Mayo-Wilson E, et al. Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. Cochrane Database Syst Rev. 2010(12):CD008524.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
John Browning, MD, provides practical skincare reminders ahead of summer season
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
Staphylococcus aureus risk in infants and neonatologist considerations with Aaron Milstone, MD
How fragrance plays a role in atopic dermatitis treatments, with John Browning, MD
Octavio Ramilo, MD, reacts to the FDA approval of clesrovimab for RSV prevention | Image Credit: St. Jude Children's Research Hospital
© 2025 MJH Life Sciences

All rights reserved.